IgG Fc N-glycosylation in guillain-barré syndrome treated with immunoglobulins

Journal of Proteome Research

Volumn 13, Issue 3, 2014, Pages 1722-1730

  Fokkink, Willem Jan R ^a   Selman, Maurice H J ^b   Dortland, Juliette R ^a   Durmuş, Büşra ^a   Kuitwaard, Krista ^a   Huizinga, Ruth ^a   Van Rijs, Wouter ^a   Tio Gillen, Anne P ^a   Van Doorn, Pieter A ^a   Deelder, André M ^b   Wuhrer, Manfred ^b   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antibody glycosylation; biomarker; glycopeptides; Guillain Barr syndrome; intravenous immunoglobulin; mass spectrometry

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; METHYLPREDNISOLONE; PLACEBO;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLYCOSYLATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIALYLATION; TREATMENT OUTCOME;

ADULT; AGED; CARBOHYDRATE SEQUENCE; FEMALE; GALACTOSE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SIALIC ACIDS; TREATMENT OUTCOME;

EID: 84896786420     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr401213z     Document Type: Article

References (49)

1. van Doorn, P. A.; Ruts, L.; Jacobs, B. C. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome Lancet Neurol. 2008, 7 (10) 939-50
2. Chavada, G.; Willison, H. J. Autoantibodies in immune-mediated neuropathies Curr. Opin. Neurol. 2012, 25 (5) 550-5
3. Ang, C. W.; Jacobs, B. C.; Laman, J. D. The Guillain-Barre syndrome: a true case of molecular mimicry Trends Immunol. 2004, 25 (2) 61-6
4. Plomp, J. J.; Molenaar, P. C.; O'Hanlon, G. M.; Jacobs, B. C.; Veitch, J.; Daha, M. R.; van Doorn, P. A.; van der Meche, F. G.; Vincent, A.; Morgan, B. P.; Willison, H. J. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates Ann. Neurol. 1999, 45 (2) 189-99
5. Susuki, K.; Rasband, M. N.; Tohyama, K.; Koibuchi, K.; Okamoto, S.; Funakoshi, K.; Hirata, K.; Baba, H.; Yuki, N. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers J. Neurosci. 2007, 27 (15) 3956-67
6. Hughes, R. A.; Swan, A. V.; van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barre syndrome Cochrane Database Syst. Rev. 2012, 7, CD002063
7. Gelfand, E. W. Intravenous immune globulin in autoimmune and inflammatory diseases N. Engl. J. Med. 2012, 367 (21) 2015-25
8. van Doorn, P. A. Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS) Presse Med. 2013, 42, e193-e201
9. Kuitwaard, K.; de Gelder, J.; Tio-Gillen, A. P.; Hop, W. C.; van Gelder, T.; van Toorenenbergen, A. W.; van Doorn, P. A.; Jacobs, B. C. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome Ann. Neurol. 2009, 66 (5) 597-603
10. Anthony, R. M.; Nimmerjahn, F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo Curr. Opin. Organ Transplant. 2011, 16 (1) 7-14
11. Kobata, A. The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles Biochim. Biophys. Acta 2008, 1780 (3) 472-8
12. Huhn, C.; Selman, M. H.; Ruhaak, L. R.; Deelder, A. M.; Wuhrer, M. IgG glycosylation analysis Proteomics 2009, 9 (4) 882-913
13. Nezlin, R.; Ghetie, V. Interactions of immunoglobulins outside the antigen-combining site Adv. Immunol. 2004, 82, 155-215
14. Rademacher, T. W.; Williams, P.; Dwek, R. A. Agalactosyl glycoforms of IgG autoantibodies are pathogenic Proc. Natl. Acad. Sci. U. S. A. 1994, 91 (13) 6123-7
15. Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 2006, 313 (5787) 670-3
16. Anthony, R. M.; Nimmerjahn, F.; Ashline, D. J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, J. V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc Science 2008, 320 (5874) 373-6
17. Bohm, S.; Schwab, I.; Lux, A.; Nimmerjahn, F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG Semin. Immunopathol. 2012, 34 (3) 443-53
18. Karsten, C. M.; Pandey, M. K.; Figge, J.; Kilchenstein, R.; Taylor, P. R.; Rosas, M.; McDonald, J. U.; Orr, S. J.; Berger, M.; Petzold, D.; Blanchard, V.; Winkler, A.; Hess, C.; Reid, D. M.; Majoul, I. V.; Strait, R. T.; Harris, N. L.; Kohl, G.; Wex, E.; Ludwig, R.; Zillikens, D.; Nimmerjahn, F.; Finkelman, F. D.; Brown, G. D.; Ehlers, M.; Kohl, J. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1 Nat. Med. 2012, 18, 1401-1406
19. Burton, D. R.; Dwek, R. A. Immunology. Sugar determines antibody activity Science 2006, 313 (5787) 627-8
20. Wuhrer, M.; Stam, J. C.; van de Geijn, F. E.; Koeleman, C. A.; Verrips, C. T.; Dolhain, R. J.; Hokke, C. H.; Deelder, A. M. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum Proteomics 2007, 7 (22) 4070-81
21. Selman, M. H.; McDonnell, L. A.; Palmblad, M.; Ruhaak, L. R.; Deelder, A. M.; Wuhrer, M. Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry Anal. Chem. 2010, 82 (3) 1073-81
22. Alavi, A.; Axford, J. S. Sweet and sour: the impact of sugars on disease Rheumatology (Oxford) 2008, 47 (6) 760-70
23. Lux, A.; Aschermann, S.; Biburger, M.; Nimmerjahn, F. The pro and anti-inflammatory activities of immunoglobulin G Ann. Rheum. Dis. 2010, 69 (Suppl 1) i92-96
24. Aschermann, S.; Lux, A.; Baerenwaldt, A.; Biburger, M.; Nimmerjahn, F. The other side of immunoglobulin G: suppressor of inflammation Clin. Exp. Immunol. 2010, 160 (2) 161-7
25. van der Meche, F. G.; Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group N. Engl. J. Med. 1992, 326 (17) 1123-9
26. van Koningsveld, R.; Schmitz, P. I.; Meche, F. G.; Visser, L. H.; Meulstee, J.; van Doorn, P. A.; Dutch, G. B. S. s. g. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial Lancet 2004, 363 (9404) 192-6
27. Asbury, A. K.; Cornblath, D. R. Assessment of current diagnostic criteria for Guillain-Barre syndrome Ann. Neurol. 1990, 27 (Suppl) S21-4
28. Kleyweg, R. P.; van der Meche, F. G.; Schmitz, P. I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome Muscle Nerve 1991, 14 (11) 1103-9
29. Hughes, R. A.; Newsom-Davis, J. M.; Perkin, G. D.; Pierce, J. M. Controlled trial prednisolone in acute polyneuropathy Lancet 1978, 2 (8093) 750-3
30. van Koningsveld, R.; Steyerberg, E. W.; Hughes, R. A.; Swan, A. V.; van Doorn, P. A.; Jacobs, B. C. A clinical prognostic scoring system for Guillain-Barre syndrome Lancet Neurol. 2007, 6 (7) 589-94
31. Selman, M. H.; Derks, R. J.; Bondt, A.; Palmblad, M.; Schoenmaker, B.; Koeleman, C. A.; van de Geijn, F. E.; Dolhain, R. J.; Deelder, A. M.; Wuhrer, M. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface J. Proteomics 2012, 75 (4) 1318-29
32. Nevedomskaya, E.; Derks, R.; Deelder, A. M.; Mayboroda, O. A.; Palmblad, M. Alignment of capillary electrophoresis-mass spectrometry datasets using accurate mass information Anal. Bioanal. Chem. 2009, 395 (8) 2527-33
33. Bondt, A.; Selman, M. H.; Deelder, A. M.; Hazes, J. M.; Willemsen, S. P.; Wuhrer, M.; Dolhain, R. J. Association between Galactosylation of Immunoglobulin G and Improvement of Rheumatoid Arthritis during Pregnancy Is Independent of Sialylation J. Proteome Res. 2013, 12 (10) 4522-4531
34. Guo, N.; Liu, Y.; Masuda, Y.; Kawagoe, M.; Ueno, Y.; Kameda, T.; Sugiyama, T. Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides Clin. Biochem. 2005, 38 (2) 149-53
35. Croce, A.; Firuzi, O.; Altieri, F.; Eufemi, M.; Agostino, R.; Priori, R.; Bombardieri, M.; Alessandri, C.; Valesini, G.; Saso, L. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis J. Clin. Lab. Anal. 2007, 21 (5) 303-14
36. Parekh, R.; Roitt, I.; Isenberg, D.; Dwek, R.; Rademacher, T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG J. Exp. Med. 1988, 167 (5) 1731-6
37. Ruhaak, L. R.; Uh, H. W.; Beekman, M.; Koeleman, C. A.; Hokke, C. H.; Westendorp, R. G.; Wuhrer, M.; Houwing-Duistermaat, J. J.; Slagboom, P. E.; Deelder, A. M. Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with human longevity PLoS One 2010, 5 (9) e12566
38. Pucic, M.; Knezevic, A.; Vidic, J.; Adamczyk, B.; Novokmet, M.; Polasek, O.; Gornik, O.; Supraha-Goreta, S.; Wormald, M. R.; Redzic, I.; Campbell, H.; Wright, A.; Hastie, N. D.; Wilson, J. F.; Rudan, I.; Wuhrer, M.; Rudd, P. M.; Josic, D.; Lauc, G. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations Mol. Cell. Proteomics 2011, 10 (10) M111 010090
39. van de Geijn, F. E.; Wuhrer, M.; Selman, M. H.; Willemsen, S. P.; de Man, Y. A.; Deelder, A. M.; Hazes, J. M.; Dolhain, R. J. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study Arthritis Res. Ther. 2009, 11 (6) R193
40. Schroeder, H. W., Jr.; Cavacini, L. Structure and function of immunoglobulins J. Allergy Clin. Immunol. 2010, 125 (2 Suppl 2) S41-52
41. Jones, A. J.; Papac, D. I.; Chin, E. H.; Keck, R.; Baughman, S. A.; Lin, Y. S.; Kneer, J.; Battersby, J. E. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys Glycobiology 2007, 17 (5) 529-40
42. Millward, T. A.; Heitzmann, M.; Bill, K.; Langle, U.; Schumacher, P.; Forrer, K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice Biologicals 2008, 36 (1) 41-7
43. Newkirk, M. M.; Novick, J.; Stevenson, M. M.; Fournier, M. J.; Apostolakos, P. Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice Clin. Exp. Immunol. 1996, 106 (2) 259-64
44. Scallon, B. J.; Tam, S. H.; McCarthy, S. G.; Cai, A. N.; Raju, T. S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality Mol. Immunol. 2007, 44 (7) 1524-34
45. Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action Trends Pharmacol. Sci. 2009, 30 (7) 356-62
46. Raju, T. S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs Curr. Opin. Immunol 2008, 20 (4) 471-8
47. Banda, N. K.; Wood, A. K.; Takahashi, K.; Levitt, B.; Rudd, P. M.; Royle, L.; Abrahams, J. L.; Stahl, G. L.; Holers, V. M.; Arend, W. P. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies Arthritis Rheum. 2008, 58 (10) 3081-9
48. Anthony, R. M.; Ravetch, J. V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs J. Clin. Immunol. 2010, 30 (Suppl 1) S9-14
49. Lehmann, B.; Schwab, I.; Bohm, S.; Lux, A.; Biburger, M.; Nimmerjahn, F. FcgammaRIIB: a modulator of cell activation and humoral tolerance Expert Rev. Clin. Immunol. 2012, 8 (3) 243-54